Christopher Michael Rose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher Michael Rose has a total of 469 co-authors. Here are the top co-authors by number of shared publications:
- Steven P. Gygi
Department of Cell Biology, Harvard Medical School, Boston, MA, USA
29 shared publications - Alain Charest
Beth Israel Deaconess Medical Center
27 shared publications - Alan T. Yeo
Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts
25 shared publications - Frederick S. Varn
The Jackson Laboratory for Genomic Medicine, Farmington, USA
25 shared publications - Hemant Varma
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School
25 shared publications - Joon Yoon
Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, Republic of Korea
25 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Cell-type-specific surfaceome profiling of 100-500 isolated cells using a droplet-based Magnetic Affinity Purification System
Cell surface proteins represent an important source of biomarkers and therapeutic targets. However, due to the inherent sensitivity limitations of existing technologies, tissue and cell-type-specific surfaceomes remain poorly characterized, especially in the context of human diseases. Here, we present nanoMAPS (nanoscale Magnetic Affinity Purification System), a miniaturized proteomic sample preparation method for surfaceome profiling of as few as 100-500 cells (~100,000-fold lower than existing technologies). By performing magnetic bead-based affinity purification within a single microliter-scale droplet, nanoMAPS significantly improves the recovery of surface proteins and reduces non-specific absorption of intracellular proteins. Application of nanoMAPS to primary human immune cells and mouse plasma cell populations enables robust identification of established cell-type-specific surface markers as well as other proteins selectively enriched in disease-associated immune cell subpopulations. Together, these results establish nanoMAPS as a broadly applicable platform for extending surface proteomics technology to rare primary cells isolated directly from diseased tissues.
- 18 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCell-type-specific surfaceome profiling of 100-500 isolated cells using a droplet-based Magnetic Affinity Purification System
Cell surface proteins represent an important source of biomarkers and therapeutic targets. However, due to the inherent sensitivity limitations of existing technologies, tissue and cell-type-specific surfaceomes remain poorly characterized, especially in the context of human diseases. Here, we present nanoMAPS (nanoscale Magnetic Affinity Purification System), a miniaturized proteomic sample preparation method for surfaceome profiling of as few as 100-500 cells (~100,000-fold lower than existing technologies). By performing magnetic bead-based affinity purification within a single microliter-scale droplet, nanoMAPS significantly improves the recovery of surface proteins and reduces non-specific absorption of intracellular proteins. Application of nanoMAPS to primary human immune cells and mouse plasma cell populations enables robust identification of established cell-type-specific surface markers as well as other proteins selectively enriched in disease-associated immune cell subpopulations. Together, these results establish nanoMAPS as a broadly applicable platform for extending surface proteomics technology to rare primary cells isolated directly from diseased tissues.
- Open Access
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Loss of MIB1 amplifies BMP target gene expression. A, Overview of the BMP inhibitor washout experiment for RNA-seq. MIB1 KO was induced by Dox (0.5 μg/mL) under BMP-off conditions (+LDN, 50 nmol/L). After 3 days, cells were split equally into medium containing BMP4 (10 ng/mL) with or without continued LDN (50 nmol/L) treatment, generating groups 1 to 4 as indicated. RNA was harvested 24 hours later for sequencing analysis. B, In parallel with RNA collection, BMP pathway activity was assessed by IB detection of SMAD1/5/9 phosphorylation 24 hours after washout of the BMP inhibitor. This confirmed effective pathway suppression and reactivation. C, RNA-seq analysis of gene expression changes following BMP inhibitor washout (n = 3 per group; 16,400 genes analyzed). The dashed line indicates genes with equivalent FC upon BMP reactivation (BMP-on/BMP-off) in both MIB1 KO and MIB1 WT cells. Potentiated BMP target genes are labeled in bold orange; other BMP target genes and pathway components are indicated with blue labels. D, Zoomed-in view of the region in C highlighting potentiated genes (orange), with BMP target genes in bold orange. E, GSEA of RNA-seq data from the BMP inhibitor washout experiment (C and D), comparing group 4 (MIB1 KO, BMP-on) with group 2 (MIB1 WT, BMP-on). Gene sets were derived from the Hallmark database. [A, Created in BioRender. Cottonham, C. (2026) https://BioRender.com/5qnb2jv.]
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Loss of MIB1 amplifies BMP target gene expression. A, Overview of the BMP inhibitor washout experiment for RNA-seq. MIB1 KO was induced by Dox (0.5 μg/mL) under BMP-off conditions (+LDN, 50 nmol/L). After 3 days, cells were split equally into medium containing BMP4 (10 ng/mL) with or without continued LDN (50 nmol/L) treatment, generating groups 1 to 4 as indicated. RNA was harvested 24 hours later for sequencing analysis. B, In parallel with RNA collection, BMP pathway activity was assessed by IB detection of SMAD1/5/9 phosphorylation 24 hours after washout of the BMP inhibitor. This confirmed effective pathway suppression and reactivation. C, RNA-seq analysis of gene expression changes following BMP inhibitor washout (n = 3 per group; 16,400 genes analyzed). The dashed line indicates genes with equivalent FC upon BMP reactivation (BMP-on/BMP-off) in both MIB1 KO and MIB1 WT cells. Potentiated BMP target genes are labeled in bold orange; other BMP target genes and pathway components are indicated with blue labels. D, Zoomed-in view of the region in C highlighting potentiated genes (orange), with BMP target genes in bold orange. E, GSEA of RNA-seq data from the BMP inhibitor washout experiment (C and D), comparing group 4 (MIB1 KO, BMP-on) with group 2 (MIB1 WT, BMP-on). Gene sets were derived from the Hallmark database. [A, Created in BioRender. Cottonham, C. (2026) https://BioRender.com/5qnb2jv.]
- Open Access
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Proteomic workflow and phosphorylation analysis under different BMP signaling conditions.
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Proteomic workflow and phosphorylation analysis under different BMP signaling conditions.
- Open Access
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Loss of MIB1 enhances BMP signaling activity. A, Immunoblot analysis of pSMAD1/5/9 levels in MIB1-iKO cells treated with Dox (0.5 μg/mL) and BMP inhibitor LDN (50 nmol/L) for 3 days. β-Actin served as the loading control. B, IF analysis of pSMAD1/5/9 (green) with DAPI (blue) nuclear staining in cells treated as described in A; scale bars, 50 μm. C, Phospho-SMAD1/5/9 (orange) or pSMAD2/3 (orange) were evaluated by IF in NCI-H838 cells transfected with MIB1 or nontargeting control (NTC) siRNA for 48 hours, with DAPI nuclear staining (blue); scale bar, 50 μm. D, Immunoblot analysis of pSMAD1/5/9 in additional MIB1- and FKBP1A-dependent cancer cell lines transfected with MIB1 or NTC siRNA for 48 to 72 hours. β-Actin served as the loading control. E, Top, schematic of the dTAG-MIB1 construct that expresses a FKBP12F36V–MIB1 fusion protein (dTAG-MIB1, Cas9-resistant) that is degraded upon addition of dTagV-1 ligand. E, Bottom, proof-of-concept experiment: NCI-H838 MIB1-iKO cells engineered to express dTAG-MIB1 and were treated with Dox (0.5 μg/mL), dTagV-1 (100 nmol/L), or a combination of both. After 24 hours, MIB1 protein levels were analyzed by IB. β-Actin served as the loading control. F, Time-course analysis using IB to assess MIB1 and pSMAD1/5/9 protein levels after different durations of dTagV-1 (100 nmol/L) in dTAG-MIB1 cells. β-Actin served as the loading control. G, pSMAD1/5/9 protein level in dTAG-MIB1 cells grown in 0.4%, 2%, or 10% serum 18 hours prior to dTagV-1 ligand treatment. β-Actin served as the loading control. Data are representative of three independent experiments. [E (top), Created in BioRender. Cottonham, C. (2026) https://BioRender.com/jbpsnmi.]
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Loss of MIB1 enhances BMP signaling activity. A, Immunoblot analysis of pSMAD1/5/9 levels in MIB1-iKO cells treated with Dox (0.5 μg/mL) and BMP inhibitor LDN (50 nmol/L) for 3 days. β-Actin served as the loading control. B, IF analysis of pSMAD1/5/9 (green) with DAPI (blue) nuclear staining in cells treated as described in A; scale bars, 50 μm. C, Phospho-SMAD1/5/9 (orange) or pSMAD2/3 (orange) were evaluated by IF in NCI-H838 cells transfected with MIB1 or nontargeting control (NTC) siRNA for 48 hours, with DAPI nuclear staining (blue); scale bar, 50 μm. D, Immunoblot analysis of pSMAD1/5/9 in additional MIB1- and FKBP1A-dependent cancer cell lines transfected with MIB1 or NTC siRNA for 48 to 72 hours. β-Actin served as the loading control. E, Top, schematic of the dTAG-MIB1 construct that expresses a FKBP12F36V–MIB1 fusion protein (dTAG-MIB1, Cas9-resistant) that is degraded upon addition of dTagV-1 ligand. E, Bottom, proof-of-concept experiment: NCI-H838 MIB1-iKO cells engineered to express dTAG-MIB1 and were treated with Dox (0.5 μg/mL), dTagV-1 (100 nmol/L), or a combination of both. After 24 hours, MIB1 protein levels were analyzed by IB. β-Actin served as the loading control. F, Time-course analysis using IB to assess MIB1 and pSMAD1/5/9 protein levels after different durations of dTagV-1 (100 nmol/L) in dTAG-MIB1 cells. β-Actin served as the loading control. G, pSMAD1/5/9 protein level in dTAG-MIB1 cells grown in 0.4%, 2%, or 10% serum 18 hours prior to dTagV-1 ligand treatment. β-Actin served as the loading control. Data are representative of three independent experiments. [E (top), Created in BioRender. Cottonham, C. (2026) https://BioRender.com/jbpsnmi.]
- Open Access
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Dependency scores for MIB1- and FKBP1A-dependent cell lines derived from DepMap analysis
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Dependency scores for MIB1- and FKBP1A-dependent cell lines derived from DepMap analysis
- Open Access
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Transcriptomic analysis of gene expression changes following modulation of BMP signaling.
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Transcriptomic analysis of gene expression changes following modulation of BMP signaling.
- Open Access
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Expression of TGF-β family receptors and SMAD signaling activity in MIB1- and FKBP1A-dependent cell lines.
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Expression of TGF-β family receptors and SMAD signaling activity in MIB1- and FKBP1A-dependent cell lines.
- Open Access
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Data from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Mind bomb 1 (MIB1), an E3 ubiquitin ligase required for NOTCH activation, has been identified as a strongly selective cancer dependency in genome-wide loss-of-function screens in more than 1,000 cancer cell lines. However, MIB1-correlating dependencies in these screens unexpectedly linked MIB1 not to Notch but rather to the family of transforming growth factor-β and bone morphogenic protein (BMP) signaling molecules. In this study, using genetic and pharmacologic methods, we show that MIB1 loss phenocopies BMP tumor-suppressive function. MIB1-dependent cancer cell lines were sensitive to BMP ligands, and MIB1 loss selectively enhanced BMP signaling, as evidenced by SMAD1/5/9 phosphorylation and transcriptional responses that correlated with increased BMP receptor protein levels. Growth inhibition and enhanced signaling were both reversed by inhibitors of BMP type 1 receptors, demonstrating that these MIB1 effects directly reflect a function for MIB1 as a negative regulator of BMP signaling. Unlike wild-type MIB1, reexpression of RING domain–deleted MIB1 failed to rescue growth inhibition in MIB1-depleted cells, suggesting that negative regulation depends on E3 ligase activity. Supporting this regulatory role, we found that MIB1 and the BMP type II receptor BMPR2 physically associate in both cancer and endothelial cells. By revealing this previously unknown role for MIB1 as a Notch-independent negative regulator of BMP signaling, our study expands the significance of MIB1 in cancer biology, with implications for targeting BMP signaling in cancer and other diseases. Significance:This study identifies MIB1 as a Notch-independent, E3 ligase–dependent regulator of BMP signaling through control of BMPR2 protein abundance, revealing a mechanistic vulnerability in BMP-responsive cancers and a potential therapeutic target.
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Mind bomb 1 (MIB1), an E3 ubiquitin ligase required for NOTCH activation, has been identified as a strongly selective cancer dependency in genome-wide loss-of-function screens in more than 1,000 cancer cell lines. However, MIB1-correlating dependencies in these screens unexpectedly linked MIB1 not to Notch but rather to the family of transforming growth factor-β and bone morphogenic protein (BMP) signaling molecules. In this study, using genetic and pharmacologic methods, we show that MIB1 loss phenocopies BMP tumor-suppressive function. MIB1-dependent cancer cell lines were sensitive to BMP ligands, and MIB1 loss selectively enhanced BMP signaling, as evidenced by SMAD1/5/9 phosphorylation and transcriptional responses that correlated with increased BMP receptor protein levels. Growth inhibition and enhanced signaling were both reversed by inhibitors of BMP type 1 receptors, demonstrating that these MIB1 effects directly reflect a function for MIB1 as a negative regulator of BMP signaling. Unlike wild-type MIB1, reexpression of RING domain–deleted MIB1 failed to rescue growth inhibition in MIB1-depleted cells, suggesting that negative regulation depends on E3 ligase activity. Supporting this regulatory role, we found that MIB1 and the BMP type II receptor BMPR2 physically associate in both cancer and endothelial cells. By revealing this previously unknown role for MIB1 as a Notch-independent negative regulator of BMP signaling, our study expands the significance of MIB1 in cancer biology, with implications for targeting BMP signaling in cancer and other diseases. Significance:This study identifies MIB1 as a Notch-independent, E3 ligase–dependent regulator of BMP signaling through control of BMPR2 protein abundance, revealing a mechanistic vulnerability in BMP-responsive cancers and a potential therapeutic target.
- Open Access
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
The ligase domains of MIB1 are essential for its regulatory function in BMP. A, Top, schematic (modified from (20)) of the endogenous MIB1 coding region, with exons shown as boxes and protein domains indicated. A, Bottom, Cas9-resistant MIB1 cDNA constructs, containing mutated PAM sequences (asterisks), express either WT MIB1 cDNA (MIB1 WT, blue) or MIB1 cDNA with all three RING domains deleted (MIB1ΔR1-3, orange). B, Immunoblot analysis of MIB1 protein levels in MIB1-iKO cells that were engineered to stably express Cas9-resistant MIB1 WT or MIB1 ΔR1-3 after 3 days of Dox (0.5 μg/mL) treatment. β-Actin served as the loading control. C–E, MIB1-iKO cells overexpressing MIB1 WT or MIB1ΔR1–3 were treated with Dox (0.5 μg/mL) for the indicated time points. C, Colony formation assay after 14 days of Dox treatment; scale bars, 10 mm. Images are representative of three independent experiments. D, CellTiter-Glo assay after 7 days of Dox treatment. Data represent three independent experiments. Two-way ANOVA with Tukey test; *, P < 0.05. “ns” denotes nonsignificant differences between no MIB1 cDNA cells and those expressing MIB1 constructs. E, Immunoblot analysis of BMPR2 immunoprecipitates from MIB1-iKO cells. Lane labels indicate MIB1 WT (no cDNA, −Dox), MIB1 KO (no cDNA, +Dox; Dox-induced KO of endogenous MIB1), MIB1 WT OE (MIB1-mNeonGreen expressed in MIB1 KO cells), and MIB1ΔR1-3 OE (MIB1ΔR1-3-IRES-mNeonGreen expressed in MIB1 KO cells). Cell lysates were subjected to IP with anti-BMPR2 antibody or IgG control, followed by IB with the indicated antibodies. Input lysates are shown for comparison. A longer exposure of the MIB1 immunoblot is included to facilitate detection of MIB1 in BMPR2 immunoprecipitates. Blue and orange arrowheads indicate BMPR2-associated MIB1 WT OE and MIB1ΔR1-3 OE, respectively. β-Actin is shown as an input and specificity control. F, Densitometric quantification of MIB1 and BMPR2 protein levels from the input immunoblots shown in E. Signals were normalized to β-Actin and expressed relative to the MIB1 WT (no cDNA, −Dox) control.
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
The ligase domains of MIB1 are essential for its regulatory function in BMP. A, Top, schematic (modified from (20)) of the endogenous MIB1 coding region, with exons shown as boxes and protein domains indicated. A, Bottom, Cas9-resistant MIB1 cDNA constructs, containing mutated PAM sequences (asterisks), express either WT MIB1 cDNA (MIB1 WT, blue) or MIB1 cDNA with all three RING domains deleted (MIB1ΔR1-3, orange). B, Immunoblot analysis of MIB1 protein levels in MIB1-iKO cells that were engineered to stably express Cas9-resistant MIB1 WT or MIB1 ΔR1-3 after 3 days of Dox (0.5 μg/mL) treatment. β-Actin served as the loading control. C–E, MIB1-iKO cells overexpressing MIB1 WT or MIB1ΔR1–3 were treated with Dox (0.5 μg/mL) for the indicated time points. C, Colony formation assay after 14 days of Dox treatment; scale bars, 10 mm. Images are representative of three independent experiments. D, CellTiter-Glo assay after 7 days of Dox treatment. Data represent three independent experiments. Two-way ANOVA with Tukey test; *, P < 0.05. “ns” denotes nonsignificant differences between no MIB1 cDNA cells and those expressing MIB1 constructs. E, Immunoblot analysis of BMPR2 immunoprecipitates from MIB1-iKO cells. Lane labels indicate MIB1 WT (no cDNA, −Dox), MIB1 KO (no cDNA, +Dox; Dox-induced KO of endogenous MIB1), MIB1 WT OE (MIB1-mNeonGreen expressed in MIB1 KO cells), and MIB1ΔR1-3 OE (MIB1ΔR1-3-IRES-mNeonGreen expressed in MIB1 KO cells). Cell lysates were subjected to IP with anti-BMPR2 antibody or IgG control, followed by IB with the indicated antibodies. Input lysates are shown for comparison. A longer exposure of the MIB1 immunoblot is included to facilitate detection of MIB1 in BMPR2 immunoprecipitates. Blue and orange arrowheads indicate BMPR2-associated MIB1 WT OE and MIB1ΔR1-3 OE, respectively. β-Actin is shown as an input and specificity control. F, Densitometric quantification of MIB1 and BMPR2 protein levels from the input immunoblots shown in E. Signals were normalized to β-Actin and expressed relative to the MIB1 WT (no cDNA, −Dox) control.
- Open Access
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Functional assays examining the effects of MIB1 perturbation on SMAD signaling and cell growth.
- 17 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling
Functional assays examining the effects of MIB1 perturbation on SMAD signaling and cell growth.